Phosphodiesterase Type 5 Inhibitor Use Among Pregnant and Reproductive‐Age Women in the United States

Basic Details
Monday, October 5, 2020

The purpose of this analysis was to assess the prevalence and potential indications of phosphodiesterase type 5 (PDE5) inhibitor use among pregnant and reproductive‐age women in the United States.

We identified women 15 to 50 years with a livebirth from January 2001 through March 2018 in Sentinel Database. We assessed the prevalence of PDE5 inhibitor use prior to and during pregnancy by trimester, identified potential on‐ and off‐label indications using predefined diagnosis codes recorded within 90 days before the estimated last menstrual period through delivery. Separately, we used data from IQVIA's National Prescription Audit and Total Patient Tracker to estimate the dispensed prescriptions for PDE5 inhibitors and the number of patients with PDE5 inhibitor prescriptions.


Wei Liu, Talia J. Menzin, Corinne M. Woods, Nicole R. Haug, Jie Li, Justin A. Mathew, Christine P. Nguyen, Grace P. Chai, David G. Moeny, Mayura Shinde

Corresponding Author

Wei Liu; Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA